 |
Advances in Schizophrenia Management: The Need for Individualized Treatment CME Author Information and Disclosures Release Date: September 30, 2008; Valid for credit through September 30, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Use emerging data to explore unique pharmacologic profiles of antipsychotic agents in terms of efficacy and tolerability
- Discuss all available antipsychotic formulations in terms of benefits, drawbacks, and individualizing treatment based on the
latest data
- Explore various psychosocial treatment strategies that can increase adherence and identify which therapies are appropriate for which patient
Authors and Disclosures Leslie Citrome, MD, MPH
Disclosure: Leslie L. Citrome, MD, MPH, has disclosed that he owns a small amount of common stock in Bristol-Myers
Squibb, Eli Lilly, Johnson & Johnson, Pfizer, and Merck, and that he has received funding for research contracts from AstraZeneca, Azur, Barr, Bristol-Myers Squibb, Eli Lilly, Forest, Janssen, and Pfizer. Dr. Citrome has also disclosed that he has served as an advisor or consultant to Avanir, Azur, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Jazz, Pfizer, and Vanda. He has also disclosed that he has served on the speaker's bureau for AstraZeneca, Azur,
Eli Lilly, and Pfizer. Matthew J. Byerly, MD
Disclosure: Matthew J. Byerly, MD, has disclosed that he has received grants for clinical research from AstraZeneca, served as an advisor or consultant to Bristol-Myers Squibb and Janssen, and served on the speaker’s bureaus of Bristol-Myers Squibb and Pfizer. Peter J. Weiden, MD
Disclosure:
Peter J. Weiden, MD, has disclosed that he has received grant support from AstraZeneca, Bristol-Myers Squibb/Otsuka America Pharmaceutical, Janssen, and Pfizer, Inc. He has also disclosed that he has served as a speaker and/or consultant to AstraZeneca, Bristol-Myers Squibb, Janssen, and Pfizer, Inc. Dr. Weiden also has disclosed that he has served as a consultant to Bristol-Myers Squibb and Otsuka America Pharmaceutical Co., Organon, Shire, Vanda, and Wyeth.
Jane Lowers
Disclosure: Jane Lowers has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
